As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The disappointing Pynnacle trial is set to yield registrational data.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
A single but durable stable disease sends the microcap's stock up 730%.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
